Mark Litzow, MD
Enriched profileProfessor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN); Head of the Acute Leukemia and Myeloid Neoplasm Group · Mayo Clinic
Mark Litzow is Professor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN); Head of the Acute Leukemia and Myeloid Neoplasm Group at Mayo Clinic. OpenAlex indexes 1,323 publications with 48,382 citations (h-index 106); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Mark Litzow, M.D., is Professor of Medicine, Division of Hematology, Mayo Clinic (Rochester, MN). The public record shows 1,323 publications with 48,382 citations (h-index 106), centered on Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 9 companies, 1 NIH-funded awards (2001–2003).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Acute Myeloid Leukemia Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 156 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 507.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Sponsor: National Cancer Institute (NCI)
- Analysis of Biomarkers for Acute Graft-versus-Host Disease (GVHD)
Sponsor: Mayo Clinic
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202511 payments$38,915openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
25.9%Beta blocker13.5%Metoprolol Succinate54%Carvedilol46%Part D<11 patientsStatin12.4%Rosuvastatin Calcium100%Part D<11 patientsCancer & immunology
23.8%Kinase inhibitor14%Jakafi56%Imatinib Mesylate44%Part D<11 patientsAntimetabolite9.8%Hydroxyurea100%Part D<11 patientsAnti-infectives
19.2%Penicillin-class Antibacterial19.2%Penicillin V Potassium100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2001–2003 per NIH RePORTER. The latest:
- DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
Mayo Clinic Coll of Medicine, Rochester
FY2003$283,392R01CA084368 - DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
Mayo Clinic Coll of Medicine, Rochester
FY2002$385,731R01CA084368 - DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
Mayo Clinic Coll of Medicine, Rochester
FY2001$374,591R01CA084368
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.
Science signaling
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/mark-litzow-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/mark-litzow-7a844a15b
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/mark-litzow-a9021319a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DQxvHCmDIhy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
vjhemonc.com/speaker/mark-litzow
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Fellowship
Hematology and Medical Oncology, Mayo Clinic College of Medicine and Science (Rochester), 1986-1989 (NOTE: fresh-pass input listed this as "completed 1990" sourced to Healthgrades …
1990verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- Board Certified
American Board of Internal Medicine: Internal Medicine, Hematology, Medical Oncology, and Hospice and Palliative Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Former Chair
Leukemia Committee, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) -- chaired 2013-2022, succeeded by Selina M. Luger, MD as of December 2022 (PAST role …
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog-ecog-acrin.org ↗ - Former Director
Blood and Marrow Transplant (BMT) Program, Mayo Clinic (1992-2008); remains actively involved in the BMT program in an unspecified capacity (PAST directorship, ongoing informal involvement)
2008verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bmtinfonet.org ↗ - Head
Acute Leukemia and Myeloid Neoplasm Group / Acute Leukemia Group, Division of Hematology, Mayo Clinic (current)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.elsevierpure.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →intheloop.mayoclinic.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →intheloop.mayoclinic.org ↗
- YouTube interview series (OncLive/Targeted Oncology producer): "Personalized Leukemia Treatment For Older Adults With ALL"
"How Genomic Risk And Immunotherapy Shape ALL Treatment" …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic